|
|
| Volume 17 • Issue 7 |
April 5, 2017 |
 |
|
|
 |
| |
 |
|
|
INTRODUCING LANCORATM
Servier Canada Inc. is pleased to announce that LANCORATM (ivabradine)
is now available.
Read more
|
|
 |
|
|
| |
 |
|
|
NOW AVAILABLE IN CANADA
PRDYSPORT THERAPEUTICTM (abobotulinumtoxinA for injection).
Read more
|
|
|
|
 |
| |
 |
|
|
VYVANSE* 70 MG STRENGTH IS NOW AVAILABLE
*VYVANSE is a registered trade-mark used under licence from Shire LLC.
Read more
|
|
 |
| |
 |
|
|
ROBAXISAL® IS NOW DYE-FREE
Pfizer Consumer Healthcare Canada, the makers of the Robax® brand, would like to
inform you that Robaxisal® is now DYE-FREE.
Read more
|
|
 |
| |
 |
|
|
IMPORTANT INFORMATION ABOUT UPCOMING ALLERGY SEASON
For many of your patients, allergy season is approaching. While some patients’ allergies are triggered year-round by dust mites, pet dander and mold, for others, it’s the outdoor seasonal triggers.
Read more
|
|
|
|
| |
 |
|
|
IMPORTANT INFORMATION
PROLENSATM LABEL CHANGE
Bausch + Lomb Canada would like to inform you that there has been a label change for the product PROLENSATM.
Read more
|
|
|
|
| |
 |
|
|
IMPORTANT INFORMATION
DISCONTINUATION OF LOTEMAX® SUSPENSION 0.5% W/V (5 ML)
Bausch + Lomb Canada would like to inform you that by the end of March 2017,
LOTEMAX® Suspension 0.5% w/v (5 mL only) will be discontinued.
Read more
|
|
|
|
| |
 |
|
|
IMPORTANT INFORMATION
NOW AVAILABLE IN CANADA
Help treat the itch associated with Allergic Conjunctivitis.
Read more
|
|
|
|
